Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) Invested Capital (2020 - 2025)

GeneDx Holdings has reported Invested Capital over the past 6 years, most recently at $362.7 million for Q4 2025.

  • Quarterly results put Invested Capital at $362.7 million for Q4 2025, up 44.48% from a year ago — trailing twelve months through Dec 2025 was $362.7 million (up 44.48% YoY), and the annual figure for FY2025 was $362.7 million, up 44.48%.
  • Invested Capital for Q4 2025 was $362.7 million at GeneDx Holdings, up from $347.1 million in the prior quarter.
  • Over the last five years, Invested Capital for WGSWW hit a ceiling of $648.3 million in Q2 2022 and a floor of -$565.2 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $307.6 million (2023), compared with a mean of $252.4 million.
  • Peak annual rise in Invested Capital hit 296.71% in 2021, while the deepest fall reached 282.55% in 2021.
  • GeneDx Holdings' Invested Capital stood at $399.1 million in 2021, then tumbled by 34.85% to $260.0 million in 2022, then fell by 9.88% to $234.3 million in 2023, then rose by 7.14% to $251.0 million in 2024, then surged by 44.48% to $362.7 million in 2025.
  • The last three reported values for Invested Capital were $362.7 million (Q4 2025), $347.1 million (Q3 2025), and $332.3 million (Q2 2025) per Business Quant data.